ESR1 and breast carcinoma: To examine whether the NO synthase-sGC signaling pathway is functional in human breast cancer cells, we measured the effects of bradykinin, a NO activator, on the production of cGMP in human 184A1 breast epithelial cells, human ER-positive MCF-7 breast cancer cells, and ER-negative MDA-MB-231 breast cancer cells.